About me
Dr. Liang is a Pharmacology/Toxicology Reviewer in the Office of Tissues and Advanced Therapies (OTAT) in the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA). She joined OTAT in 2006. Her primary focus is the review of preclinical testing program including in vitro and in vivo animal studies that are intended to support the conduct of clinical studies of cellular and gene therapy-based products as well as some blood products for various indications.
